AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01195688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: oral doses given to 2 subjects per dose group
Study NCT03082014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: blood pressure lowering agent - dihydropyridine Ca2+-channel blocker
Study NCT03082014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: blood pressure lowering agent - angiotensin-receptor blockers
Study NCT03082014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: blood pressure lowering agent - beta-blocker
Study NCT00928733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastroduodenoscopy- Intraduodenal intubation
Description: 20 g ethanol diluted up to 10% in tap water
Study NCT03960164 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dermal regeneration photosynthetic matrix (DRPM)
Description: Primary Procedure: DRPM implantation~1. Wound bed preparation and cleaning.~2. DRPM implantation.~3. Illumination with LED device.~Secondary Procedure: Autologous partial skin graft
Study NCT02648867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Maternal Feedback
Description: The PushCoach device consists of a modification of the standard fetal scalp electrode and a separate apparatus designed to detect movement of the fetal head by detecting movement of an FSE. The PushCoach will be attached to the patient by an adhesive pad over the sacrum and extend between the patient's legs approximately 2-3 inches from the vaginal introitus. It assesses the movement of the FSE attached to the fetal scalp during pushing. The amount of fetal movement will be measured and recorded. The PushCoach device is connected to a laptop computer which will provide optical and auditory feedback to the patient about descent of the fetal head with maternal expulsive efforts.
Study NCT02648867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Maternal Feedback
Description: The PushCoach device consists of a modification of the standard fetal scalp electrode and a separate apparatus designed to detect movement of the fetal head by detecting movement of an FSE. The PushCoach will be attached to the patient by an adhesive pad over the sacrum and extend between the patient's legs approximately 2-3 inches from the vaginal introitus. It assesses the movement of the FSE attached to the fetal scalp during pushing. The amount of fetal movement will be measured and recorded. The PushCoach device is connected to a laptop computer which will provide optical and auditory feedback to the patient about descent of the fetal head with maternal expulsive efforts.
Study NCT01236131 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: Not Applicable- no intervention
Study NCT01910870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks
Study NCT01910870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronomic Cyclophosphamide
Description: 150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks
Study NCT02221154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inofolic®
Study NCT00882193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine
Description: Betaine 20 gm/day in 2 divided doses for 48 weeks
Study NCT02221154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins; Folic Acid
Description: standard ovarian stimulation
Study NCT02221154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gonadotropins; Folic Acid
Description: standard ovarian stimulation
Study NCT02546960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC4V (4 : 4 : 4 : 4)
Description: Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle in part 1 (age groups >=18 to \<50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in microgram \[mcg\]) from the ExPEC serotypes O1A, O2, O6A, and O25B.
Study NCT02546960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC4V (4 : 4 : 4 : 8)
Description: Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to \<50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
Study NCT02546960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC4V (8 : 8 : 8 : 8)
Description: Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to \<50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
Study NCT02546960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC4V (8 : 8 : 8 : 16)
Description: Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to \<50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
Study NCT02546960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC4V (16 : 16 : 16 : 16)
Description: Participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to \<50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
Study NCT02546960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
Study NCT00392652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral microencapsulated diindolylmethane
Description: Given PO
Study NCT02254902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity intervention
Description: The Physical Activity intervention is a 3-month group-based program based on an efficacious physical activity intervention that has been culturally adapted for use with adult Somali women. The program targets increased physical activity through educational and experiential opportunities.
Study NCT02546960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
Study NCT00473603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipid/heparin infusion
Description: to perform an i.v. lipid heparin infusion infusion for 4 h
Study NCT00473603 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: lipid/heparin infusion
Description: to perform an i.v. lipid heparin infusion infusion for 4 h
Study NCT04869033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Farinelli's Breathing Exercise
Description: after 1 minute of normal breathing, follow this instruction; inhale 2 seconds, suspend 2 seconds, exhale 2 seconds. inhale 3 seconds, suspend 3 seconds, exhale 3 seconds. inhale 4 seconds, suspend 4 seconds, exhale 4 seconds. inhale 5 seconds, suspend 5 seconds, exhale 5 seconds. inhale 6 seconds, suspend 6 seconds, exhale 6 seconds. This cycle lasted 1 minute (60 seconds), called Farinelli's breathing (FB). When participants finished these cycle, repeated it again 4 times. 1 minute of NB + 4 minutes of FB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
Study NCT04869033 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diaphragmatic Breathing Exercise
Description: after 1 minute of normal breathing, inhale 2 seconds and exhale 2 seconds with nasal airway. Continued breathing this pattern until 4 minutes, then back to normal breathing 1 minute . 1 minute of NB + 4 minute of DB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
Study NCT00882193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha 2a
Description: Peginterferon alpha 2a 180mcg/0.5ml by subcutaneous injection weekly for 48 weeks
Study NCT00882193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 200mg - weight based, 1000 - 1200 mg/day for body weight \< or > 75mg in 2 divided doses
Study NCT03849859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single plastic stent
Description: Deployment of single plastic stent
Study NCT03849859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple plastic stents
Description: Deployment of multiple plastic stents
Study NCT04639609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Characterization of Neuromuscular Function and Fatigue
Description: at inclusion
Study NCT04639609 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Characterization of Neuromuscular Function and Fatigue
Description: at inclusion
Study NCT04475679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhese Universal DC
Description: Adhese Universal DC, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic to bond indirect restorations to the tooth surface
Study NCT04475679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adhese Universal
Description: Adhese Universal, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic to bond indirect restorations to the tooth
Study NCT03060447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablets Administered orally
Study NCT03060447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets Administered orally
Study NCT03060447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART
Description: ART regimens administered in accordance with their prescribing information. The following agents are allowed as part of the ART regimen: nucleoside reverse transcriptase inhibitors, raltegravir, dolutegravir (DTG), rilpivirine, and maraviroc.
Study NCT00525174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bangerter filters
Description: Bangerter filter worn on sound eye spectacle lens full time
Study NCT00525174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: 2 hours daily patching of the sound eye
Study NCT00525174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near activities
Description: one hour near visual activities
Study NCT02383433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study NCT02676765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allergen extract tablet
Description: 1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
Study NCT02676765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
Study NCT02763826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: brain stimulation using progressively increasing amounts of direct currents and in a variety of electrode montages
Study NCT03222232 — intervention group
Intervention type: BEHAVIORAL
Intervention: catheter salvage
Description: In each case of catheter-related bloodstream infection the management of the central venous catheter was registred to evaluate the future risk of new infections
Study NCT01858688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI
Description: an MRI of the prostate will be performed
Study NCT01858688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Description: a biopsy of the prostate will be performed according to standard procedures for men on active surveillance
Study NCT02013804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0680 (AMP-514)
Description: Study has planned dose escalation cohorts
Study NCT03368274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T 614
Description: Patients of IgG4-RD with mild symptoms are given one dose of diprospan and Iguratimod, 25mg, Bid.
Study NCT01631409 — intervention group
Intervention type: OTHER
Intervention: Treatment of CHD risk factors
Description: Smoking cessation, low fat diet, body weight control, physical exercise program, and in some cases lipid-lowering medications, e.g. 3-hydroxy-3-methylglutaric acid-coenzyme A (HMG-CoA) reductase inhibitors, e.g. Simvastatin.
Study NCT01631409 — intervention group
Intervention type: DRUG
Intervention: Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.
Description: In the course of optimal medical treatment of Cohort I patient the life style modification is combined with one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) and lipid-lowering drugs (e.g. HMG-CoA reductase inhibitors).
Study NCT01631409 — intervention group
Intervention type: DRUG
Intervention: Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.
Description: In the course of maximal antianginal medical therapy a Cohort II patient is provided with more than one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
Study NCT02122029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counselling
Description: Behavioral techniques for weight management
Study NCT02122029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Description: Vertical Banding Gastroplasty
Study NCT02640690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Center Trauma Sensitive Yoga Intervention (TCTSY)
Description: (10) 1-hour sessions of trauma sensitive yoga
Study NCT02640690 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: (12) 1.5 hour sessions of cognitive processing therapy
Study NCT01631409 — intervention group
Intervention type: PROCEDURE
Intervention: PCA
Description: Percutaneous coronary angioplasty
Study NCT01631409 — intervention group
Intervention type: PROCEDURE
Intervention: CABG
Description: Coronary artery bypass grafting
Study NCT02383433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT03382067 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Epicatechin/ Melissa
Description: Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa chocolate + 7.2g caster sugar + 5g Melissa
Study NCT03382067 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low Epicatechin/ Oat bran
Description: Single consumption of a 55g bar of white chocolate containing: 50g Lindor chocolate + 5g oat bran
Study NCT02955680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: recorded maternal voice
Description: A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath.  At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up.
Study NCT02955680 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: recorded stranger's voice
Description: A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath.
Study NCT04515953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-340
Description: ND-340: Subjects will receive a single administration of ND-340 at the specified dose in each arm after TKA.
Study NCT04515953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV-PCA
Description: IV-PCA: Intravenous patient-controlled analgesia (IV-PCA), morphine, will be administered in subjects of control group after TKA for postoperative pain management as standard practice.
Study NCT03149952 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells
Description: Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells.
Study NCT01102894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartPill
Description: SmartPill
Study NCT04720768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: MEK inhibitor
Study NCT04720768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: BRAF inhibitor
Study NCT04720768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK4/6 inhibitor
Study NCT01711866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine up to 16 mg / 24 hours, 4 weeks.
Study NCT04353882 — intervention group
Intervention type: OTHER
Intervention: Assess the difference in MOR-1 expression between healthy and tumor tissue
Description: Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.
Study NCT02666794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural bupivacaine with vasoconstrictor 0.125%
Description: 10 ml
Study NCT02666794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural sufentanil
Description: 20 mcg
Study NCT02666794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of the epidural catheter
Description: Placement of the epidural catheter
Study NCT02666794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal hyperbaric bupivacaine solution 0.5%
Description: 2.5 mg
Study NCT02666794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: 60 mcg
Study NCT02666794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of an epidural catheter to the catheter through technical needle
Description: Placement of an epidural catheter to the catheter through technical needle
Study NCT02666794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal sufentanil
Description: 5 mcg
Study NCT01133015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve
Description: Fractional flow reserve measured by pressure wire
Study NCT01133015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVUS
Description: intravascular ultrasound
Study NCT01076621 — intervention group
Intervention type: DRUG
Intervention: 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)
Description: Data collection of the use of 0.5 mg estradiol and 0.1 mg norethisterone acetate (NETA) in women in connection to a daily clinical practice.
Study NCT01986959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: With Periodontal dressing
Description: After surgery,the dressing was mixed with a sterile spatula on a sterile glass plate following the manufacturer's instructions (2 cm of each paste measured with a sterile endodontic ruler). Coe-PakTM Regular was the dressing employed. Mixing and placement were performed only by the specialists in periodontics to ensure standardization. The dressing was inserted into the surgical wounds and molded to the necessary shape after setting sufficiently. The removal of the periodontal dressing was done after seven days.
Study NCT01986959 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Without Periodontal dressing
Description: The dressing was not inserted.
Study NCT02068261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cogmed working memory training
Description: Computerized working memory training with Cogmed QM software. The QM software consists of a set of verbal and visual working memory tasks which is trained for 25-40 minutes each session.
Study NCT02015780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasiglifam
Description: Fasiglifam tablets
Study NCT02015780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fasiglifam placebo-matching tablets
Study NCT02015780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihyperglycemic therapy
Description: Including any of the following alone or in combination: insulin, sulfonylurea, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, alpha-glucosidase inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors acceptable by local practice guidelines.